7753-60-8

7753-60-8 structure

Name: Anecortave Acetate
Chemical Name: [2-[(8S,10S,13S,14S,17R)-17-hydroxy-10,13-dimethyl-3-oxo-2,6,7,8,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate
CAS Number: 7753-60-8
Molecular Formula: C₂₃H₃₀O₅
Molecular Weight: 386.48100
Catalog: Signaling Pathways Metabolic Enzyme/Protease PAI-1
Create Date: 2018-09-01 17:43:01
Modify Date: 2024-01-04 23:27:30
Anecortave acetate is a potent ocular angiostatic agent. Anecortave acetate inhibits neovascularization which is induced by many different angiogenic factors, and increases plasminogen activator inhibitor-1 (PAI-1) mRNA expression. Anecortave acetate can be used to research ocular neovascular diseases[1][2].

Name	[2-[(8S,10S,13S,14S,17R)-17-hydroxy-10,13-dimethyl-3-oxo-2,6,7,8,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate
Synonyms	2-((10S,13S,17R)-17-hydroxy-10,13-dimethyl-3-oxo-2,3,6,7,8,10,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate 21-Acetoxy-17-hydroxy-pregna-4,9(11)-dien-3,20-dion Retaane 21-acetoxy-17-hydroxy-pregna-4,9(11)-diene-3,20-dione AL-3789 2-((8S,10S,13S,14S,17R)-17-hydroxy-10,13-dimethyl-3-oxo-2,3,6,7,8,10,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate Anecortave Anecortave acetate Retaane suspension

Description	Anecortave acetate is a potent ocular angiostatic agent. Anecortave acetate inhibits neovascularization which is induced by many different angiogenic factors, and increases plasminogen activator inhibitor-1 (PAI-1) mRNA expression. Anecortave acetate can be used to research ocular neovascular diseases[1][2].
Related Catalog	Signaling Pathways >> Metabolic Enzyme/Protease >> PAI-1 Research Areas >> Cardiovascular Disease
Target	PAI-1[2]
In Vivo	Anecortave acetate (5 μl of a 10% suspension; Injected into eyes) significantly inhibits pathologic retinal angiogenesis and increases PAI-1 mRNA levels[2]. Animal Model: Sprague-Dawley albino rats (intravitreally injected with premixed antibiotics to influence retinal vessel growth)[2] Dosage: 5 μl of a 10% suspension of Anecortave acetate Administration: Injected into eyes Result: significantly inhibited pathologic retinal angiogenesis in this model, while not significantly affecting normal intraretinal vessels. Increased 6-to-9-fold PAI-1 mRNA at 1 to 3 days after injection.